Table 1

Demographic and baseline characteristics by treatment arm

CharacteristicSham pooled
(N=65)
PEOM
(N=61)
P value versus shamPM
(N=71)
P value versus shamAll
(N=197)
Gender
 Female39 (60.0%)40 (65.6%)45 (63.4%)124 (62.9%)
 Male26 (40.0%)21 (34.4%)26 (36.6%)73 (37.1%)
Age (years)
 Mean (SD)77.9 (7.58)80.3 (7.43)80.4 (7.44)79.5 (7.53)
 Median (Min, Max)78.0 (60.0, 96.0)80.0 (60.0, 97.0)81.0 (63.0, 95.0)80.0 (60.0, 97.0)
Baseline VA (ETDRS letters)
 Mean (SD)52.4 (22.5)56.3 (20.1)55.5 (19.0)54.7 (20.5)
 Median (Min, Max)58.0 (0, 85.0)60.0 (4.00, 89.0)58.0 (0, 83.0)59.0 (0, 89.0)
RORA (mm2)
 Mean (SD)7.10 (3.63)7.36 (3.62)0.6606.59 (2.94)0.5787.00 (3.39)
 Median (Min, Max)6.33 (2.02, 16.6)7.74 (2.08, 15.5)6.05 (1.59, 13.8)6.33 (1.59, 16.6)
PRD (mm2)
 Mean (SD)12.8 (5.51)13.6 (5.89)0.55712.5 (4.64)0.79413.0 (5.33)
 Median (Min, Max)12.3 (3.35, 26.4)13.8 (3.53, 26.4)12.0 (4.54, 24.3)12.6 (3.35, 26.4)
PRD in isolation (mm2)
 Mean (SD)5.12 (2.87)5.76 (3.71)0.6805.53 (2.96)0.6805.47 (3.18)
 Median (Min, Max)4.59 (0.690, 14.7)4.77 (1.08, 17.8)4.50 (1.25, 14.3)4.61 (0.690, 17.8)
RPE loss (mm2)
 Mean (SD)7.71 (4.03)7.91 (3.82)0.7567.06 (3.04)0.4407.54 (3.64)
 Median (Min, Max)7.09 (2.43, 21.4)7.79 (2.24, 15.9)6.54 (1.99, 14.3)6.92 (1.99, 21.4)
Hypertransmission (mm2)
 Mean (SD)8.18 (3.92)8.67 (3.93)0.6017.84 (3.34)0.6018.21 (3.72)
 Median (Min, Max)7.60 (2.60, 19.3)8.73 (2.57, 17.2)7.39 (1.73, 15.7)7.80 (1.73, 19.3)
Intact macula (mm2)
 Mean (SD)13.7 (5.92)13.5 (5.97)0.77714.5 (4.99)0.64913.9 (5.61)
 Median (Min, Max)13.9 (0.202, 24.0)13.2 (0.360, 24.1)14.1 (1.67, 23.6)13.9 (0.202, 24.1)
Perimeter (mm)
 Mean (SD)23.9 (10.3)24.7 (11.2)0.95523.8 (11.7)0.95524.1 (11.1)
 Median (Min, Max)21.9 (7.19, 60.9)24.4 (7.56, 58.4)19.6 (7.21, 55.3)21.9 (7.19, 60.9)
Focality
 Mean (SD)2.94 (2.08)3.43 (2.48)0.5713.07 (2.38)0.7413.14 (2.32)
 Median (Min, Max)2.00 (1.00, 10.0)3.00 (1.00, 10.0)2.00 (1.00, 12.0)2.00 (1.00, 12.0)
  • ETDRS, Early Treatment of Diabetic Retinopathy Study; PEOM, pegcetacoplan every other month; PM, pegcetacoplan monthly; PRD, photoreceptor degeneration; RORA, RPE and outer retinal atrophy; RPE, retinal pigment epithelium; VA, Visual Acuity.